Health Care [ 3/12 ] | Health Care Equipment & Supplies [ 22/74 ]
NYSE | Common Stock
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
It operates in two segments, Proprietary Products and Contract-Manufactured Products.
The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.
This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support.
This segment serves biologic, generic, and pharmaceutical drug companies.
The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
The company serves pharmaceutical, diagnostic, and medical device companies.
It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors.
West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 24, 24 | 1.85 Decreased by -14.35% | 1.50 Increased by +23.33% |
| Jul 25, 24 | 1.52 Decreased by -27.96% | 1.74 Decreased by -12.64% |
| Apr 25, 24 | 1.56 Decreased by -21.21% | 1.26 Increased by +23.81% |
| Feb 15, 24 | 1.83 Increased by +3.39% | 1.78 Increased by +2.81% |
| Oct 26, 23 | 2.16 Increased by +6.40% | 1.86 Increased by +16.13% |
| Jul 27, 23 | 2.11 Decreased by -14.57% | 1.93 Increased by +9.33% |
| Apr 27, 23 | 1.98 Decreased by -13.91% | 1.67 Increased by +18.56% |
| Feb 16, 23 | 1.77 Decreased by -13.24% | 1.38 Increased by +28.26% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 746.90 M Decreased by -0.07% | 136.00 M Decreased by -15.69% | Increased by +18.21% Decreased by -15.63% |
| Jun 30, 24 | 702.00 M Decreased by -6.87% | 111.30 M Decreased by -28.24% | Increased by +15.85% Decreased by -22.94% |
| Mar 31, 24 | 695.40 M Decreased by -2.96% | 115.30 M Decreased by -17.64% | Increased by +16.58% Decreased by -15.13% |
| Dec 31, 23 | 732.00 M Increased by +3.29% | 137.00 M Increased by +33.01% | Increased by +18.72% Increased by +28.78% |
| Sep 30, 23 | 747.40 M Increased by +8.81% | 161.30 M Increased by +33.75% | Increased by +21.58% Increased by +22.92% |
| Jun 30, 23 | 753.80 M Decreased by -2.27% | 155.10 M Decreased by -17.72% | Increased by +20.58% Decreased by -15.81% |
| Mar 31, 23 | 716.60 M Decreased by -0.47% | 140.00 M Decreased by -19.45% | Increased by +19.54% Decreased by -19.07% |
| Dec 31, 22 | 708.70 M Decreased by -3.02% | 103.00 M Decreased by -30.26% | Increased by +14.53% Decreased by -28.09% |